Palvella Therapeutics PVLA Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by Palvella Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The official record: Palvella Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Palvella Therapeutics's net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Palvella Therapeutics's net change in cash?
- Palvella Therapeutics (PVLA) reported net change in cash of $148.41M in Q1 2026.
- How has Palvella Therapeutics's net change in cash changed year-over-year?
- Palvella Therapeutics's net change in cash increased by 1960.7% year-over-year, from -$7.98M to $148.41M.
- What is the long-term trend for Palvella Therapeutics's net change in cash?
- Over 3 years (2022 to 2025), Palvella Therapeutics's net change in cash has grown at a -31.3% compound annual growth rate (CAGR), from -$79.13M to -$25.62M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.